The Committee for Medicinal Products for Human Use (CHMP) has recommended that a fixed-duration regimen of Calquence ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the CD30-directed antibody-drug conjugate (ADC ...

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo's ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Halozyme Therapeutics (NASDAQ:HALO) announced Monday that an expert panel of the EU ...

Argenx has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended European Commission (EC) ...

EMA committee recommends approval of AstraZeneca’s fixed-duration Calquence-based regimens for 1st-line chronic lymphocytic leukaemia: Cambridge, UK Wednesday, April 30, 2025, 1 ...

AstraZeneca has announced that a fixed-duration regimen of Calquence (acalabrutinib) in combination with venetoclax, with or ...

The drug receives conditional marketing authorization by the CHMP for the treatment of HER2-positive biliary tract cancer.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Takeda has announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending European ...

The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending a change to the terms of the marketing ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523) ...